The FDA Peptide Decision of July 2026: What’s Actually Changing

On July 23 and 24, 2026, an FDA advisory committee spent two days deciding whether seven peptides can be legally compounded for patients. Three of them, Semax, Epitalon, and BPC-157, are the ones I get asked about most weeks. The rules for FDA peptide compounding have already moved twice in three years, and this vote is the next step.

For a substance-by-substance read of how strong the human evidence actually is, see my breakdown of what the July 2026 peptide vote does and the evidence behind it.

For the semax-specific legal status, including why a listing may not be limited to the use assessed, see my full semax analysis.

Here is what is actually on the table, because the headlines are already getting it wrong. The Pharmacy Compounding Advisory Committee is not approving these peptides as drugs. It voted on whether to move them toward the 503A Bulks List, which governs what a compounding pharmacy is allowed to make for an individual prescription. The vote is a recommendation, and it is non-binding. Even if every peptide gets a yes, the FDA still has to write a formal rule, and that process routinely runs more than a year.

I am board-certified in both adult and forensic psychiatry. I read regulatory records as part of my work, and I prescribe within the evidence and within the law. So this article does two things. It explains, in plain terms, what the FDA is reviewing and what it would mean for access. And it tells you what the human evidence actually shows for each peptide, including the ones where the honest answer is that we mostly have animal studies.

The uses the FDA is reviewing are not the uses these peptides are marketed for online. The agency is evaluating Semax for cerebral ischemia, migraine, and trigeminal neuralgia, not for the anxiety and focus claims that fill the forums.

Update, July 24, 2026: Both days are done. The FDA’s Pharmacy Compounding Advisory Committee recommended six of the seven peptides for the 503A compounding list, going against the FDA scientists who had urged rejecting all seven. On day one, BPC-157, KPV, and TB-500 each cleared 8-6 with one abstention, and MOTS-c cleared 7-5 with two abstentions. On day two, semax cleared 8-5 with one abstention, and epitalon cleared as well, reported as 7-4 with one abstention by most outlets and 7-5 by one specialist publication. DSIP, listed on the agenda as emideltide, is the only one the committee voted down, 6-7 with one abstention. These votes are advisory and non-binding: the FDA still has to accept them and complete rulemaking, usually 12 to 24 months, before access changes. FDA hasn’t posted the official meeting record yet, so the tallies come from reporters at the meeting.

What the FDA peptide compounding vote actually decides

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the rules for compounding: the practice of a licensed pharmacy making a drug to order for one patient. To compound with a raw substance that has no FDA-approved version and no official quality monograph, that substance has to sit on a list the FDA maintains, the 503A Bulks List. Two buckets matter here. Category 1 substances can be used while the FDA finishes its review. Category 2 substances cannot be used at all.

The status of these peptides has already moved once this year, which is where the confusion starts. The FDA put them in Category 2 back in September 2023, citing limited human data, manufacturing impurities, and immunogenicity, the risk that an injected peptide triggers an immune response. In the spring of 2026 the agency removed twelve peptides, including all seven on this agenda, from Category 2.

Removal from Category 2 sounds like a green light. It is not. With the exception of GHK-Cu, none of these peptides were moved into Category 1, and none appear on the FDA’s nomination lists. So right now they sit in a gray zone. They are no longer labeled a significant safety risk, and they are also not authorized for compounding. A pharmacy that reads “removed from Category 2” as permission is taking on real enforcement risk.

What the committee votes on next month is whether to move these substances toward Category 1 and the Bulks List. Two days, seven substances, a short presentation from each nominator, and a public comment window. The docket, FDA-2025-N-6895, closes July 22, 2026.

A yes vote changes less than it sounds. The recommendation is non-binding, so the FDA can accept it, modify it, or set it aside. Even full acceptance triggers notice-and-comment rulemaking before anything becomes legal, and on this particular list that has taken one to two years, sometimes longer. The realistic near-term outcome is a recommendation, a proposed rule, and a wait.

There is one wildcard worth naming. HHS Secretary Robert F. Kennedy Jr. has said publicly that the prohibition pushed patients toward an unregulated market, and that an announcement could come within weeks. The Secretary does have statutory authority to act before the committee process finishes if he decides it protects public health, but that is speculation until it happens, and I will not build a treatment plan on a maybe.

Why these seven, and why now

The short version: politics and demand collided with a thin evidence base, and the FDA is trying to build a process around a market that already exists.

Peptides moved from bodybuilding forums into mainstream telehealth fast, sold direct to consumers and marketed hard by compounding pharmacies. That demand did not disappear when the 2023 restriction landed. It moved to a gray and black market with far less oversight, which is the exact argument the current administration now uses for loosening the rules.

The meeting is the FDA doing the procedural work it skipped before. Under its own process, changes to the Bulks List run through this advisory committee. Without that step, any change invites a legal challenge. A second committee meeting is already planned before the end of February 2027 to review five more peptides, including GHK-Cu, Melanotan II, and Cathelicidin.

For my patients, the timing matters for one practical reason. Search interest and gray-market selling both spike around a vote like this. The science does not change on July 24. The hype does.

The evidence, substance by substance

This is where a clinical read separates from a sales pitch. I have sorted these seven by how much human evidence actually exists, not by how loudly they are marketed. When the honest answer is “animal studies only,” I say so.

BPC-157

The use under review is ulcerative colitis. BPC-157 has the most real clinical history of the group: as PL14736, it went through early human trials for inflammatory bowel disease (PMID 18818478). Beyond gut disease, the human data thins out fast. One small orthopedic report described relief in 7 of 12 patients with chronic knee pain after a single injection (PMID 40756949), and a 2026 pilot tested intravenous safety in two healthy adults (PMID 40131143). A Phase 2 trial in acute hamstring injury is now registered (NCT07437547), which is the kind of controlled data the field has lacked. Recent reviews still call it investigational, with efficacy “yet to be confirmed in humans” (PMID 30915550). I go deeper in my review of the BPC-157 research. My read: a genuine early signal in IBD, and a lot of marketing that runs ahead of the data.

KPV

The uses under review are wound healing and inflammatory conditions. KPV is a three-amino-acid fragment of a hormone called alpha-MSH, and it does have plausible anti-inflammatory mechanisms (PMID 28143741). But the studies are in cells and animals. I could not find human therapeutic trials. That does not make it useless. It makes it unproven in people.

TB-500

The use under review is wound healing, and this one needs a correction that almost nobody selling it makes. The human evidence belongs to thymosin beta-4, the full natural peptide, which sped healing in two phase 2 ulcer trials (PMID 23050815). TB-500 is a fragment, not the same molecule, and one analysis suggests its reported activity may come from a breakdown product (PMID 38382158). If you are sold “TB-500” on the strength of thymosin beta-4 studies, you are being sold one thing on the evidence for another.

MOTS-c

The uses under review are obesity and osteoporosis. MOTS-c is a peptide your own mitochondria make, and the research is genuinely interesting: it behaves like an exercise mimetic and improves insulin sensitivity (PMID 25738459, PMID 33473109). Every one of those studies is in mice. There are no human therapeutic trials. Any mental-health angle, including mine, is a hypothesis built on biology, not something the FDA is reviewing or that human data supports yet.

Emideltide (DSIP)

The uses under review are opioid withdrawal, chronic insomnia, and narcolepsy. Emideltide is the FDA’s term for delta sleep-inducing peptide. The human work here is real but old and small, including studies in alcohol and opiate withdrawal from the 1980s (PMID 6548969). I have not found modern controlled trials. For a substance now being considered for withdrawal and sleep, that is a thin file.

Semax

The uses under review are cerebral ischemia, migraine, and trigeminal neuralgia. Notice what is missing: the anxiety, depression, and focus claims that drive most online sales. Semax does have human data in stroke recovery, where it raised BDNF and sped functional recovery (PMID 29798983). Most of that work is Russian-language and single-center, which Western regulators weigh cautiously. I cover the mood and cognition questions in more depth in my clinical write-up on Semax and Selank, but the short version is that the strongest evidence is for indications people are not buying it for.

Epitalon

The use under review is insomnia, and of all the longevity claims attached to this peptide, the sleep mechanism is the most defensible. Epitalon affects the pineal gland and melatonin, and small human studies in older adults reported improvements in pineal function (PMID 17969590, PMID 12374906). The telomere and anti-aging claims rest mostly on a single human-cell study (PMID 12937682) and animal work. The retinal-disease reports are small (PMID 12195242). I walk through the sleep angle in my piece on Epitalon and melatonin.

What “reviewed use” means versus what is sold online

Read the two evidence tables in the FDA notice and a pattern jumps out. The uses the agency is reviewing often have nothing to do with the marketing.

One of the seven peptides in the July 2026 review, DSIP (emideltide), gets a full clinical read in my guide to the DSIP peptide.

Semax is under review for stroke and migraine, sold for anxiety and focus. MOTS-c is under review for obesity and osteoporosis, sold for energy and performance. TB-500 is sold on thymosin beta-4’s wound-healing data while being a different molecule. This is not a small footnote. The legal question the FDA is answering is narrow and specific, and the consumer pitch is broad and aspirational. When someone tells you the FDA is about to “approve” your peptide for the reason you want it, they are usually wrong on two counts.

The psychiatric lens, and where it honestly applies

This is my point of view layer, so I will label it clearly. The FDA is not reviewing any of these peptides for psychiatric use. I am interested in them because several touch systems I treat every day.

Epitalon and Emideltide both act on sleep, which I cover in my guide to sleep medications and peptides, and sleep sits underneath depression, anxiety, and cognitive complaints. Emideltide’s old withdrawal data connects to addiction psychiatry. Semax raises BDNF, a growth factor involved in neuroplasticity, and I weigh peptides against standard treatment in peptides versus SSRIs. MOTS-c connects to metabolic health, which overlaps with the work I do on peptides alongside psychiatric medications.

None of that means I prescribe these today, and most of it is mechanism rather than proven treatment. The honest clinical position is interest plus caution: these are worth understanding, even if they are not worth chasing through a gray market today.

Immunogenicity, impurities, and the gray-market problem

The FDA’s 2023 safety concerns did not vanish when the Category 2 label came off. They were the reason for the label in the first place.

Two risks stand out. Immunogenicity means an injected peptide can provoke an immune response, which is hard to predict and harder to undo. Impurities mean that what is in the vial may not match what is on the label, especially from unregulated suppliers. Research-grade peptides bought online are not made to pharmaceutical standards, and “not for human use” on the package is doing real legal and medical work.

For a preview, look at compounded GLP-1 drugs. The FDA has sent a stream of warning letters to compounding pharmacies and telehealth platforms over misleading claims and manufacturing failures, and there is no reason peptides will be treated more gently.

If you are in North Carolina and considering peptides

Here is what I can and cannot do, stated plainly. I cannot legally provide a Category 2 substance, and right now these peptides are not authorized for compounding. What I can do is evaluate whether a given peptide is reasonable for you, what the evidence actually supports, and what the legal status is this week, because it is moving.

That is the entire offer: a psychiatric peptide evaluation that treats candidacy, evidence, and legality as one clinical question. If access opens through a legitimate compounding pathway, you will already understand what is and is not worth pursuing. If it does not, you will have saved yourself a gray-market gamble. When you want that read on your situation, you can book a consultation.

What happens after July 24

A few scenarios are worth holding loosely.

If the committee recommends adding some of these peptides to the Bulks List, rulemaking still follows, and legal compounding could be a year or more away. If the committee declines, the gray zone hardens and the gray market keeps running. And if the Secretary acts first, on his own authority, access could open faster than the committee process implies, with the safety and quality questions still unresolved.

I will update this page after the meeting with what the committee actually recommended. Until then, the responsible move is to understand where things stand before buying anything.

Frequently asked questions

Are these peptides legal to get in North Carolina right now?

No. As of June 2026 the seven peptides on the July agenda have been removed from the FDA’s Category 2 list but have not been authorized for compounding under Category 1. They sit in a gray zone, and compounding them carries enforcement risk anywhere in the country, North Carolina included.

Is the FDA approving these peptides as drugs?

No. The Pharmacy Compounding Advisory Committee voted on whether they can be used as bulk substances in 503A compounding, which is a separate question from drug approval. The vote is also non-binding advice to the FDA.

If the committee says yes, can I get them right away?

Probably not. A favorable recommendation still has to go through formal notice-and-comment rulemaking before these substances are added to the Bulks List. On this list that has historically taken one to two years or longer.

Which peptides are being reviewed, and for what?

July 23: BPC-157 (ulcerative colitis), KPV (wound healing and inflammation), TB-500 (wound healing), and MOTS-c (obesity and osteoporosis). July 24: Emideltide/DSIP (opioid withdrawal, chronic insomnia, narcolepsy), Semax (cerebral ischemia, migraine, trigeminal neuralgia), and Epitalon (insomnia). Those are the uses the FDA reviewed, which are often not the uses these peptides are marketed for.

Does Dr. Baghel prescribe these peptides?

Not while they are unauthorized for compounding. What I provide is an evaluation: whether a given peptide is reasonable for you, what the evidence supports, and what its legal status is at the time we meet. If a legitimate compounding pathway opens, that groundwork is already done.

This article is for general educational purposes and is not medical advice. It does not establish a physician-patient relationship and is not an offer to prescribe or provide any specific substance. Peptides discussed here are not FDA-approved for the uses described, and several are not currently legal to compound. Talk with a qualified clinician about your individual situation.

References

1. FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Request for Comments. 91 FR 20465, Apr 16, 2026. Federal Register.
2. Regulations.gov. Docket FDA-2025-N-6895 (comments close Jul 22, 2026). Regulations.gov.
3. FDA. Bulk Drug Substances Used in Compounding Under Section 503A. FDA.gov.
4. FDA. Bulk Drug Substances Nominated for Use in Compounding (category lists). FDA.gov (PDF).
5. BPC-157 (PL14736) in inflammatory bowel disease trials. PMID 18818478.
6. BPC-157 in orthopedic use, chronic knee pain report. PMID 40756949.
7. BPC-157 status: investigational, efficacy unconfirmed in humans. PMID 30915550.
8. BPC-157 Phase 2 trial in acute hamstring injury (registered). ClinicalTrials.gov NCT07437547.
9. Thymosin beta-4, phase 2 trials in pressure and stasis ulcers. PMID 23050815.
10. MOTS-c regulates insulin sensitivity and metabolic homeostasis (preclinical). PMID 25738459.
11. DSIP in alcohol and opiate withdrawal syndromes. PMID 6548969.
12. Semax in stroke rehabilitation, BDNF and functional recovery. PMID 29798983.
13. Epitalon and pineal function in older adults. PMID 17969590.
14. Epithalon induces telomerase activity in human somatic cells. PMID 12937682.